Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Ligand (LGND) Breakout! -- Ignore unavailable to you. Want to Upgrade?

To: Robert L. Ray who wrote (23140)	7/13/1998 8:08:00 PM
From: Machaon	Read Replies (1) \| Respond to of 32384

<< AHP and LGND are working on drug/s that could eventually make Premarin all but a dead drug >> Your discussion of "designer hormones" was interesting, thanks. << LGND's pipeline is the deepest I've seen in any biotech I've looked at. Let's just hope it's quality pipe :) >> I think that LGND is a case where the "sum" is less than "the sum of it's parts". At a $500 million capitalization, LGND seems moderately priced, for a biotech company that doesn't have a commercialized product. But, if you would split LGND into separate pieces, as separate stocks, you'd probably get a significantly higher valuation. << Actually I don't right off hand know the details of the AHP agreement so I don't know how much of that LGND would be entitled to. >> It sure would be nice to know the exact details of the royalties. LGND also has an Estrogen Agonist program with Pfizer, in clinical trials, and has royalties and milestones connected to Pfizer's Droloxifene Osteoporosis drug, in Phase II/III trials. << I'll have to admit that Henry most definitely played a part in my decision to invest in LGND. >> He certainly wouldn't be devoting so much time to ONE biotech stock, if he didn't feel strongly that there was a pot of gold at the end of the "Ligand Rainbow". There are a lot of other fish in the ocean of biotechs. Plus, as discussed, the information about Ligand is impressive. Good luck, Bob